Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most claims relate to pill identification and manufacturer variability; the provided FDA label excerpts for Tigan do not address these topics. Claims referencing pill-ID best practices are therefore largely unsupported by the supplied prescribing information. The only label-relevant material in the prompt concerns Tigan’s dosage form/route and general safety items; none of those are asserted by the AI as medical/prescribing claims.
Category Scores
Accurate Statements
Unsupported Statements
Trimethobenzamide is available as tablets or capsules.
The supplied prescribing information excerpts describe Tigan as an injection (intramuscular only) and do not state that trimethobenzamide is available as tablets or capsules.
Different manufacturers and brands of trimethobenzamide can have different tablet/capsule shapes.
Not addressed in the provided label excerpts.
Different manufacturers and brands of trimethobenzamide can use different tablet/capsule colors.
Not addressed in the provided label excerpts.
Different manufacturers and brands of trimethobenzamide can have different imprint markings.
Not addressed in the provided label excerpts.
Different manufacturers and brands of trimethobenzamide can have different packaging designs.
Not addressed in the provided label excerpts.
Matching by imprint code is the best way to confirm the correct trimethobenzamide formulation.
The provided label excerpts do not provide pill-identification guidance or endorse imprint-code matching.
Pill identification should include cross-checking the pill’s imprint code against a reputable pill-identifier source.
Not addressed in the provided label excerpts.
Pill identification should verify that the strength and dosage form match.
Not addressed in the provided label excerpts.
Color alone should not be relied on for pill identification because similar-looking pills can exist.
Not addressed in the provided label excerpts.
Contradictions
Low
AI Statement
Trimethobenzamide is available as tablets or capsules.
Label Reference
Injection / Administration Limitations in the supplied excerpts (Tigan injection intended for intramuscular use only; not for pediatric patients).
Important Omissions
Any labeling-consistent guidance relevant to Tigan’s route/dosage form (e.g., intramuscular use only; not recommended for intravenous use) or contraindications/warnings (e.g., pediatric contraindication; drowsiness; alcohol interaction) as it relates to the pill-identification context.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The only potentially label-relevant mismatch is the assertion that trimethobenzamide is available as tablets/capsules, while the provided label excerpts focus on Tigan as an intramuscular injection. Because the rest of the claims are not supported by the supplied label, the overall content alignment is limited.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Pill-identification/manufacturer-variation claims are not supported by the supplied FDA prescribing information; additionally, the claim that trimethobenzamide is available as tablets/capsules conflicts with the provided label emphasis on injection form.
Suggested Improvement
Restrict statements to what is supported by the supplied label excerpts (indications, contraindications, warnings, and administration limitations), and avoid asserting tablet/capsule availability or pill-identification best-practice recommendations unless the prescribing information provided explicitly supports them.